Matthew B. Frieman

University of Maryland, Baltimore — United States

Medicine · Health Sciences

78h-index23.2kcitations242works4.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

SARS-CoV-2 and COVID-19 Research(153), COVID-19 Clinical Research Studies(73), Animal Virus Infections Studies(47), Viral gastroenteritis research and epidemiology(30), interferon and immune responses(27)

Publications241 total

A SARS-CoV-2 entry inhibitor trimerizes to lock the spike protein in a closed conformation
2025Open Access
The mammalian SKI complex is a broad-spectrum antiviral drug target that upregulates cellular cholesterol to inhibit viral replication
Journal of Virology·2025Open Access
Discovery, phylogenetic, and comparative genomic analysis of novel avian gammacoronaviruses identified in feral pigeons ( <i>Columba livia domestica</i> )
Journal of Virology·2025Open Access
Global siRNA screen identifies human host factors critical for SARS-CoV-2 replication and late stages of infection
PLoS Biology·2025· 4 citedOpen Access
Enhancing protective efficacy and immunogenicity of hemagglutinin-based influenza vaccine utilizing adjuvants developed by BECC
2025Open Access
Corrigendum: Placental SARS-CoV-2 Infection and Its Implications for Increased Risk of Adverse Pregnancy Outcomes
American Journal of Perinatology·2024
The mammalian SKI complex is a broad-spectrum antiviral drug target that upregulates cellular cholesterol to inhibit viral replication
2024Open Access
A trivalent mucosal vaccine encoding phylogenetically inferred ancestral RBD sequences confers pan-Sarbecovirus protection in mice
Cell Host & Microbe·2024· 13 citedOpen Access
Extracellular vesicles containing SARS‐CoV‐2 proteins are associated with multi‐organ dysfunction and worse outcomes in patients with severe COVID‐19
Journal of Extracellular Vesicles·2024· 8 citedOpen Access
The BNT162b2 mRNA vaccine demonstrates reduced age-associated TH1 support in vitro and in vivo
iScience·2024· 4 citedOpen Access
Oral pharmacokinetics and efficacy of oral phospholipid remdesivir nucleoside prodrugs against SARS-CoV-2 in mice
Antimicrobial Agents and Chemotherapy·2024· 5 citedOpen Access
Global siRNA Screen Reveals Critical Human Host Factors of SARS-CoV-2 Multicycle Replication
2024· 2 citedOpen Access
SARS-CoV-2 ORF8 modulates lung inflammation and clinical disease progression
PLoS Pathogens·2024· 10 citedOpen Access
Comparative analysis of SARS-CoV-2 neutralization titers reveals consistency between human and animal model serum and across assays
Science Translational Medicine·2024· 14 citedOpen Access
Placental SARS-CoV-2 Infection and Its Implications for Increased Risk of Adverse Pregnancy Outcomes
American Journal of Perinatology·2024· 2 cited
Association of Nirmatrelvir/Ritonavir Treatment and COVID-19-Neutralizing Antibody Titers in a Longitudinal Health Care Worker Cohort
Open Forum Infectious Diseases·2024· 2 citedOpen Access
CNP blocks mitochondrial depolarization and inhibits SARS-CoV-2 replication in vitro and in vivo
PLoS Pathogens·2023· 2 citedOpen Access
SIRT-1 is required for release of enveloped enteroviruses
eLife·2023· 2 citedOpen Access
Author Response: SIRT-1 is required for release of enveloped enteroviruses
2023Open Access
Diet-induced obesity and diabetes enhance mortality and reduce vaccine efficacy for SARS-CoV-2
Journal of Virology·2023· 17 citedOpen Access
page 1 of 13Next →

Frequent Co-authors

Ralph S. Baric(13), Stuart Weston(12), James Logue(10), Christopher M. Coleman(8), Robert Haupt(7), Marisa E. McGrath(6), Boyd L. Yount(5), Mark T. Heise(5), Gale Smith(4), Gregory M. Glenn(4), Lisa E. Gralinski(4), Adolfo Garcı́a-Sastre(4), Julie Dyall(4), Michael R. Holbrook(4), Jason Kindrachuk(4), Reed F. Johnson(4), Gene G. Olinger(4), Peter B. Jahrling(4), Lisa E. Hensley(4), Holly Hammond(4)